First Comprehensive Companion Diagnostic OK'd

Found an issue? Give us feedback

Cancer Discoveryarrow_drop_down

Cancer Discovery

Article . 2018 . Peer-reviewed

Data sources: Crossref

Cancer Discovery

Article

Data sources: Europe PubMed Central

First Comprehensive Companion Diagnostic OK'd

descriptionPublicationkeyboard_double_arrow_right Article 01 Mar 2018 English Publisher:American Association for Cancer Research (AACR)Journal:Cancer Discovery, volume 8, pages OF4-OF4 (issn: 2159-8274, eissn: 2159-8290,

Copyright policy )

doi: 10.1158/2159-8290.cd-nb2017-182

pmid: 29339360

First Comprehensive Companion Diagnostic OK'd

- Summary
- Metrics

Abstract

Abstract The FDA has approved F1CDx, a comprehensive companion diagnostic test that can detect genetic alterations and two genomic signatures in any type of solid tumor. Patients with five common types of advanced cancer can be matched to one of 17 targeted therapies with this single test.

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	3
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average